RDY News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDYPR NewswireNEW YORK, Sept. 17, 2026 NEW YORK, Sept. 17, 2026...
PR Newswire
Dr Reddy's Laboratories Q1 2027 Earnings Call Transcript
Dr Reddy's Laboratories (NYSE:RDY) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call.
This content is powered by Benzinga APIs. For comprehensive financialread more...
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY PR Newswire NEW YORK, Sept. 10, 2026 NEW YORK, Sept. 10...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY PR Newswire NEW YORK, Aug. 27, 2026 NEW YORK, Aug. 27, 2026...
PR Newswire
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
Zacks
Securities Fraud Investigation Into Dr. Reddys Laboratories (RDY) Announced Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Dr. Reddys Laboratories (Dr. Reddys or the Company) (NYSE: RDY) investors concerning the Companys possible violations of the federal securities...
Business Wire
Securities Fraud Investigation Into Dr. Reddys Laboratories (RDY) Announced Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announces an investigation of Dr. Reddys Laboratories (Dr. Reddys or the Company) (NYSE: RDY) on behalf of investors concerning the Companys possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON DR. REDDYS LABORATORIES (RDY), CLICK...
Business Wire
RDY SHAREHOLDER ALERT: Dr. Reddys Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Dr. Reddys Laboratories (Dr. Reddys or the Company) (NYSE: RDY) investors concerning the Companys and/or members of its senior managements possible violation of the federal securities laws or other unlawful...
Business Wire
Dr. Reddys Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion, in the United States
Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a generic equivalent of Bridion, in the...
Business Wire
Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky
Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky PR Newswire NEW YORK, July 31, 2026 Investigation focuses on RDY losses after Dr. Reddy's disclosed a 2.4 billion provision tied to...
PR Newswire